Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trialJ M S Bartlett, D C Sgroi, K Treuner, et al.
Oncology Reports|June 26, 2008
A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient settingS A Hussain, D H Palmer, D E Swinson, et al.
British Journal of Cancer|January 11, 2007
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancerS A Hussain, R Ganesan, G Reynolds, et al.
British Journal of Cancer|September 18, 2008
NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of lifeH M Earl, L Hiller, J A Dunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2005
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancerD W Rea, J W R Nortier, W W Ten Bokkel Huinink, et al.
British Journal of Cancer|October 15, 2014
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancerJ Stephen, G Murray, D A Cameron, et al.
British Journal of Cancer|October 5, 2013
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trialJ M S Bartlett, C L Brookes, T Piper, et al.
The British Journal of Surgery|April 16, 2010
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countriesJ G H van Nes, C Seynaeve, S Jones, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2004
A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifenS R D Johnston, L A Gumbrell, T R J Evans, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 2